Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

A 25-year-old Spanish woman has died by euthanasia after a long battle with her father over her right to die.

Noelia Castillo, a rape survivor who was left paralyzed in her lower half of the body after a suicide attempt in 2022, died on Thursday evening at a hospital in Barcelona.

While the Catalan regional government had granted her the right to assisted dying in 2024, her father, Geronimo Castillo, had raised legal objections. Her wish to ‘die in peace’ has also sparked debate around the country’s right-to-die law -- legalized in 2021.

Who Is Noelia Castillo?

Much of Castillo’s life during her childhood was spent in care homes. Her father's problems with alcohol had a significant impact on her mental health, and she underwent psychiatric treatment since her early teens.

Later, she was diagnosed with conditions including obsessive-compulsive disorder and Borderline Personality Disorder.

She was raped twice: first by an ex-boyfriend and later by three men in 2022 while at a state-supervised facility for vulnerable youth.

The assaults, which took a severe toll on her mental health, led her to make multiple suicide attempts.

In October 2022, she jumped from a fifth-floor window, which left her with a severe spinal cord injury and permanent paralysis in her lower body.

Also read: Harish Rana, India’s First Passive Euthanasia Case, Dies at AIIMS

Noelia Castillo’s Fight For Euthanasia

Castillo chose assisted dying to escape years of physical pain and emotional trauma.

In her final days, Castillo spoke openly about her suffering and her decision. In an interview with Spanish broadcaster Antena 3, she said: “I just cannot go on anymore… I want to go in peace now and stop suffering.”

Speaking earlier to Spanish TV programme Y Ahora Sonsoles, she added: “I am very clear… none of my family is in favour of euthanasia. But what about all the pain I’ve suffered during all these years?”

In 2024, the Catalan regional government granted her the right to assisted dying in 2024. But the process was suspended after legal objections raised by her father. According to her father, her mental health did not allow her to make better decisions about herself.

Noelia Castillo: 18-month-long Legal Battle

Christian Lawyers (Abogados Cristianos) had been attempting to block her death until the last moment. For 18 months, the case moved through multiple courts, eventually reaching Spain’s Constitutional Court, which ruled there was “no violation of fundamental rights” in allowing her euthanasia.

Finally, the European Court of Human Rights (ECHR) ruled this week in Noelia Castillo's favour, and her death was eventually confirmed late on Thursday.

In a TV interview this week, she said nobody in her family had supported her decision to die by euthanasia, and her father "hasn't respected my decision and never will".

"I want to go in peace now and stop suffering," she told Antena 3 TV the day before she died.

Critics Call Her Death A Failure Of The State

"For a girl who obviously has had a very tough life, which we all regret, the only thing that could be offered to her by the healthcare system is death," said José María Fernández, of Christian Lawyers.

The opposition conservative People's Party (PP), which voted against a 2021 euthanasia law, had a similar response.

Several senior Catholic leaders in Spain have sharply criticised the euthanasia of 25-year-old Noelia Castillo, calling it a reflection of societal failure and raising concerns over the country’s right-to-die law.“We have all failed as a society,” Jose Mazuelos Perez, Bishop of the Canary Islands, was quoted as saying by EuroNews.

In a joint statement, church leaders said the case reflected “an accumulation of personal suffering and institutional shortcomings”.

The BA.3.2 COVID-19 variant, nicknamed Cicada, is evading capable antibodies gained from previous vaccinations. According to experts, it is less likely that the currently available COVID vaccines will provide protection.

As per the US Centers for Disease Control and Prevention (CDC), Cicada — a highly mutated variant of COVID — has already been reported in at least 23 countries, including 25 states in America. It has also been detected in 132 wastewater samples from Massachusetts.

What Is The Cicada COVID Variant?

Cicada was first identified in a respiratory sample in South Africa in November 2024.

It is a descendant of the Omicron BA.3 lineage, and is genetically distinct from the previously circulating JN.1 lineages (including LP.8.1 and XFG).

BA.3.2 comprises two major branches, BA.3.2.1 and BA.3.2.2. BA.3.2.2 also has substitutions like: K356T, A575S, R681H, and R1162P.

The World Health Organization (WHO) has designated BA.3.2 as a Variant Under Monitoring (VUM). It means the variant may not be that dangerous yet, but it may have concerning mutations.

The CDC’s latest Morbidity and Mortality Weekly Report explains that Cicada has “70 to 75 substitutions and deletions in the gene sequence of its spike protein”.

Will Current COVID Vaccines Work?

The variant is particularly concerning as it provides no immune protection to people with previous infection or even vaccination.

“The number of mutations from JN.1 viruses makes it less likely that the current vaccines will be highly effective against Cicada, but we need more data to better answer this question,” Dr. Robert H. Hopkins Jr., medical director of the National Foundation for Infectious Diseases, told USA TODAY.

However, according to the WHO, current COVID vaccines are expected to continue protecting against severe disease. Moreover, the WHO said BA.3.2 doesn’t seem to be making people sicker so far and hasn’t resulted in increased hospitalizations and deaths.

“Overall, available evidence suggests that BA.3.2 poses low additional public health risk compared with other circulating Omicron descendant lineages,” WHO said.

And unlike previous strains, BA.3.2 hasn’t rapidly overtaken other variants; in fact, it hasn’t fueled enough cases nationally to land on the CDC’s variant tracker.

“If it had really special advantages, we’d probably have seen it take off and dominate globally relatively quickly,” Andrew Pekosz, a virologist at the Johns Hopkins Bloomberg School of Public Health, told TODAY.com. “We didn’t see that, but it’s not going away, so it’s something to keep an eye on.”

Also read: Unique Symptoms Of 'Cicada' The Highly Mutated New COVID Variant Of 2026

Will Cicada Become The Dominant COVID Strain

Hopkins Jr. expressed the possibility that "Cicada can become the dominant strain in the US”. While it is not certain, it can also "drive a US summer surge.”

The CDC has also warned that a new variant "with substantial capacity to evade immunity from previous infections or vaccines could be associated with seasonal increases in COVID-19 activity.”

Also read: COVID Variant BA.3.2 Spreads To 23 Countries: Is The Variant Under Monitoring A Cause Of Worry?

What Makes Cicada So Unique?

T Ryan Gregory, a professor of evolutionary biology at the University of Guelph stated that Cicada is emerging as a contender for the next major lineage.

He wrote on social media platform X: "Well, it's that time again. Meet "Cicada", BA.3.2* (including descendant RE.*). This one has been underground for years (its ancestor BA.3 hasn't been circulating since early 2022, and didn't do much then either) but is now emerging as a contender for the next major lineage."

While most of the symptoms of this new variant remain the same as those of the other variants, one thing that stands out here is the gastrointestinal symptoms that cicada could cause.

However, experts note that this variant will not make anyone sicker. Other symptoms include:

• Cough
• Fever or chills
• Sore throat
• Congestion
• Shortness of breath
• Loss of smell or taste
• Fatigue
• Headache.

After a recent Supreme Court of India order banning the use of stem cell therapy to treat autism -- a neurodevelopmental condition affecting communication, social interaction, and behavior -- the country's National Medical Commission has issued a clear warning to doctors and hospitals not to use the therapy to treat autism in routine medical practice.

The National Medical Commission, in a new advisory, asked all medical colleges, hospitals, and doctors to strictly follow the rules.

In a letter sent to the regulator, Indian Council of Medical Research Director-General Dr. Rajiv Bahl stated that the stem cell treatment can now be used in regular medical practice only for 32 diseases that are officially approved by the government. These include blood cancers and serious blood disorders such as:

Acute myeloid leukemia

Thalassemia

Multiple myeloma

Aplastic anemia

Myelofibrosis

Germ cell tumors.

The letter asked doctors not to offer stem cell therapy for any other disease outside this list.

Notably, the Ethics and Medical Registration Board (EMRB), under the National Medical Commission (NMC), had, in December 2022, constituted the Committee on Stem Cell Use in Autism Spectrum Disorder (ASD).

It had stated that none of the current international guidelines recommend stem cell therapy as a treatment for ASD and added that the therapy is not recommended as a treatment for ASD in clinical practice.

Also read: Japan Approves First-Ever Stem Cell Therapies For Parkinson’s And Heart Failure

What Was The Supreme Court Ruling On Stem Cells?

Earlier this year, in January, a bench comprising Justice JB Pardiwala and Justice R Mahadevan noted that stem cell therapy lacks “scientific support and has not been recognized as a sound medical practice backed by empirical evidence”.

The Bench ruled that “every use of stem cells in patients outside an approved clinical trial is unethical and shall be considered as malpractice.”

The apex Court, however, added that the advanced therapy, which holds promise in several medical fields, can still be approved for monitored clinical research trials. It added that the patients have the liberty to participate in approved and regulated clinical trials.

What Is Stem Cell Therapy

Stem cell therapy, also called regenerative medicine, is a medical treatment that uses stem cells to repair or replace damaged tissues.

While the therapy is useful and effective for blood cancers and autoimmune diseases, for the treatment of autism, there is no proof or scientific evidence of its utility.

As stem cell therapy is vastly unregulated in India, many private labs have been minting money over the promise of treatment for autism.

“Most stem cell therapies are unregulated in India and are promoted based on no evidence, and fake advertisements. While these disorders have no cure, many people are falsely lured by these companies,” Dr. Manjari Tripathi, Head of Department, Neurology, AIIMS Delhi, had told IANS, after the SC verdict.

Also read: New Stem Cell Transplant Breakthrough Could Replace Chemo In Cancer Treatment

Stem Cells Permissible Only For Research

The NMC warned that any doctor or institution offering stem cell therapy for autism will face regulatory and legal action.

The top medical regulator, however, stated that stem cell therapy is permissible only for research purposes.

Such studies must follow strict rules set by the government and must be approved by ethics committees and national regulatory bodies.

Researchers must also ensure that patients give written consent, that treatment is provided free during the trial, and compensation is offered if injury or death occurs during research.